NSAID use and risk of Parkinson disease: a population-based case-control study
about
The promise of neuroprotective agents in Parkinson's diseaseInsights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based TherapiesNeuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugsRole of microglia in CNS inflammationM1 and M2 immune activation in Parkinson's Disease: Foe and ally?Down-regulation of microglial activity attenuates axotomized nigral dopaminergic neuronal cell loss.Post-treatment with an ultra-low dose of NADPH oxidase inhibitor diphenyleneiodonium attenuates disease progression in multiple Parkinson's disease modelsEicosanoid receptor subtype-mediated opposing regulation of TLR-stimulated expression of astrocyte glial-derived neurotrophic factor.Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship.Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts.Pathways towards an effective immunotherapy for Parkinson's diseaseTargeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors.The role of glia in α-synucleinopathies.Parkinson's disease: evidence for environmental risk factors.Neuroinflammation in Parkinson's disease: role in neurodegeneration and tissue repair.l-DOPA-induced dyskinesia in Parkinson's disease: Are neuroinflammation and astrocytes key elements?Targeting Microglial Activation States as a Therapeutic Avenue in Parkinson's Disease.Patterns of anti-inflammatory drug use and risk of dementia: a matched case-control study.Updates on immunity and inflammation in Parkinson disease pathology.Inhibitory Effects of Betulinic Acid on LPS-Induced Neuroinflammation Involve M2 Microglial Polarization via CaMKKβ-Dependent AMPK Activation.Prevention of progression in Parkinson's diseaseNonsteroidal anti-inflammatory drugs use and risk of Parkinson disease: A dose-response meta-analysis
P2860
Q21129436-2902CC6E-D216-4AA8-8B0D-9339DBBC6EE3Q26795984-16140436-DCF4-4AD4-A3AE-82413B005FD6Q26801035-CF15F04C-16D9-42A4-96F5-144CD4BBA1F7Q27023760-5A1B21B9-88D7-40EE-B788-284C15CC1971Q27024667-C9DDD551-5D62-4FAA-A230-6B7C5F4A53CBQ35007941-33F4969F-042B-4488-BE01-1EC7A32424F0Q35529695-98B34A83-B951-43AE-BB52-47AEE3A236D0Q36055556-D9E8D1DE-2305-43BA-BDB6-445DADAD2DFFQ37069901-2589FAFA-61A6-4C6F-8364-9329E16AAB96Q37874476-A9111865-5581-4988-83F2-D9BC8DAEB3E6Q37957125-CE9C026F-1C19-4A12-A7BE-F3728C1A0D99Q38009736-61F9AC5A-91D4-4360-A8AA-15BA3CF6D3ACQ38039880-9D2271C7-BA61-403F-86E9-7BC12A325912Q38055457-63182457-726E-4324-ABAC-354CDFF6EDF4Q38264485-61863519-67C1-4BB4-BD41-25179AF7800EQ38951947-5D1E46D5-28FF-44BD-87E6-50DE1E51E0AFQ39392775-850FBAC7-DA1F-4D64-9285-82C20756B703Q40734133-978FD1B1-7AEF-48DC-A8DC-E64026A80AE2Q46132067-74A31B33-AC51-48C8-9C4C-C23AB06EA98BQ52581903-99442655-773E-41C9-9E1F-08A3A4CA12D9Q58486541-05045961-1526-4E70-BFAC-6E2172F352CAQ58739806-CE02318F-9743-496F-AF1D-A4966A5CA250
P2860
NSAID use and risk of Parkinson disease: a population-based case-control study
description
scientific article published on 04 April 2011
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у квітні 2011
@uk
name
NSAID use and risk of Parkinson disease: a population-based case-control study
@en
NSAID use and risk of Parkinson disease: a population-based case-control study
@nl
type
label
NSAID use and risk of Parkinson disease: a population-based case-control study
@en
NSAID use and risk of Parkinson disease: a population-based case-control study
@nl
prefLabel
NSAID use and risk of Parkinson disease: a population-based case-control study
@en
NSAID use and risk of Parkinson disease: a population-based case-control study
@nl
P2860
P1476
NSAID use and risk of Parkinson disease: a population-based case-control study
@en
P2093
P2860
P304
P356
10.1111/J.1468-1331.2011.03399.X
P50
P577
2011-04-04T00:00:00Z